Cencora, Inc. (COR)
Automate Your Wheel Strategy on COR
With Tiblio's Option Bot, you can configure your own wheel strategy including COR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COR
- Rev/Share 1657.2175
- Book/Share 9.0103
- PB 46.5133
- Debt/Equity 5.08
- CurrentRatio 0.9035
- ROIC 0.1341
- MktCap 70177128367.0
- FreeCF/Share 16.5403
- PFCF 21.8815
- PE 45.1321
- Debt/Assets 0.1
- DivYield 0.0062
- ROE 1.315
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | COR | Morgan Stanley | Equal Weight | Overweight | -- | $400 | Jan. 29, 2026 |
| Upgrade | COR | Jefferies | Hold | Buy | -- | $440 | Jan. 22, 2026 |
| Initiation | COR | Barclays | -- | Overweight | -- | $400 | Dec. 9, 2025 |
| Upgrade | COR | Wells Fargo | Equal Weight | Overweight | -- | $337 | June 3, 2025 |
| Resumed | COR | Mizuho | -- | Outperform | -- | $280 | Dec. 4, 2024 |
| Downgrade | COR | BofA Securities | Buy | Neutral | $275 | $245 | Sept. 18, 2024 |
News
Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript
Read More
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
COR shares slip despite Q1 EPS beat and revenues match estimates, margins expand and fiscal 2026 growth guidance up.
Read More
Cencora (COR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
Can Specialty and International Momentum Support Cencora's Q1 Results?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
COR's Q1 outlook is supported by specialty utilization, RCA momentum, and steady international growth, even as GLP-1 tailwinds ease.
Read More
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Why Cencora (COR) is a Top Value Stock for the Long-Term
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why You Should Retain Cencora Stock in Your Portfolio Now
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Neutral
Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.
Read More
Here's Why Cencora (COR) is a Strong Growth Stock
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
4 Stocks Trading Near 52-Week High With More Upside Potential
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Stocks like NVDA, RL, EXPE and COR are seeing price strength and have a high chance of carrying the momentum forward.
Read More
Cencora to Acquire OneOncology to Expand Community Oncology Solutions
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.
Read More
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora's U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance underscore its accelerating growth momentum.
Read More
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and CorMedix (CRMD) have performed compared to their sector so far this year.
Read More
Why Is Cencora (COR) Down 6.3% Since Last Earnings Report?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Read More
Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Cencora (COR) Upgraded to Buy: Here's Why
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Here's Why Cencora (COR) is a Strong Value Stock
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Cencora (COR) is a Strong Growth Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Cencora (COR) is a Strong Momentum Stock
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Read More
Here's Why Cencora (COR) is a Strong Growth Stock
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Cencora (COR) is a Top Value Stock for the Long-Term
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Cencora: Earnings Visibility Driving Re-Rating Potential
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora is rated a Buy, with a target price of $392, driven by strong fundamentals and sector leadership. COR's stable business model, high cash flows, low debt, and shareholder-friendly policies make it attractive for conservative, long-term investors. Recent earnings showed double-digit profit growth, robust revenue from specialty drugs, and high predictability, supporting management's optimistic forecasts.
Read More
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
COR Q4 Earnings & Revenues Beat Estimates, Gross Margin Improves
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.
Read More
Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Countdown to Cencora (COR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
About Cencora, Inc. (COR)
- IPO Date 1995-04-04
- Website https://www.cencora.com
- Industry Medical - Distribution
- CEO Robert Mauch
- Employees 47000